Products
Online Inquiry
Our Products Cannot Be Used As Medicines Directly For Personal Use.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
Bosutinib (SKI-606)
Cat No.
CEI-0265
Description
Bosutinib (SKI-606) can inhibit Src and Abl with IC50 of 1.2 nM and 1 nM.
CAS No.
380843-75-4
Molecular Weight
530.45
Purity
>99%
Storage
2 years at -20centigrade Powder
Targets
Src, Abl
Molecular Formula
C26H29Cl2N5O3
Chemical Name
4-(2,4-dichloro-5-methoxyphenylamino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile
Solubility
DMSO 110 mg/mL Water
In vitro
SKI-606 (bosutinib) is a potent, orally bioavailable, dual Src/Abl kinase inhibitor. SKI-606 can inhibit cellular Src kinase activity in intact tumor cells with IC50 of 250 nM. Besides inhibiting Src kinase, SKI-606 can also inhibit the phosphorylation of focal adhesion kinase (FAK), proline-rich tyrosine kinase 2 (Pyk2), and Crk-associated substrate (p130Cas). SKI-606 can reduce cell motility and invasion of breast cancer cell lines with an IC50 of approximately 250 nM. But SKI-606 do not influence cell proliferation and survival at this concentration.
In vivo
SKI-606 (bosutinib) has antiproliferative effects in chronic myelogenous leukemia cells, to inhibit colon tumor cell colony formation in soft agar, and to suppress tumor growth in K562 and colon tumor cell xenograft models. SKI-606 (Bosutinib) blocks prostate cancer invasion, growth, and metastasis in vitro and in vivo. Treating with SKI-606, there is a reduction in the phosphorylation of Akt, MAPK and focal adhesion kinase. Besides the inhibition to kinases, SKI-606 can decrease the level of the expression of tumor progression-associated genes uPAR, MMP-2, MMP-9, N-cadherin, fibronectin, BMP-2 (bone morphogenetic protein 2), BMP-6 (bone morphogenetic protein 6), IL-8 (interleukin 8), and TGF-beta (transforming growth factor beta) in prostate cancer cells.
Download
Download Datasheet